Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 1.00 |
| ▸ | RAF1 | P04049 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241657 | 0.89 | MAPK14 (1.00) | MAPK14RAF1ALDH1A1MAPT | |
| SCHEMBL3245596 | 0.81 | RAF1 (0.68) | MAPK14RAF1ALDH1A1MAPTPKM | |
| SCHEMBL3249076 | 0.80 | RAF1 (0.67) | MAPK14RAF1 | |
| SCHEMBL3242693 | 0.78 | MAPK14 (1.00) | MAPK14RAF1ALDH1A1MAPT | |
| SCHEMBL3237625 | 0.78 | MAPK14 (1.00) | MAPK14RAF1 | |
| SCHEMBL3226646 | 0.72 | MAPK14 (1.00) | MAPK14RAF1ALDH1A1MAPTPKM | |
| SCHEMBL3213560 | 0.72 | MAPK14 (1.00) | MAPK14RAF1 | |
| SCHEMBL3229662 | 0.72 | MAPK14 (1.00) | MAPK14RAF1ALDH1A1MAPTPKM | |
| SCHEMBL4113098 | 0.69 | MAPT (1.00) | ALDH1A1MAPTPKMATM | |
| SCHEMBL6918715 | 0.69 | MAPK14 (0.53) | MAPK14RAF1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | claimed |
| JP-4344960-B2 | — | — | 2009-10-14 | — | — | JP | claimed |
| EP-1019040-B1 | ARYL UREAS FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES | BAYER AG (US) | 2004-09-29 | — | — | EP | claimed |
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION (US) | 2002-08-01 | — | — | US | claimed |
| US-6344476-B1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION | 2002-02-05 | — | — | US | claimed |
| JP-2001526687-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-1019040-A4 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER AG (US) | 2000-10-04 | — | — | EP | claimed |
| EP-1019040-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | Bayer Corporation (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1998052558-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | claimed |
| US-9296811-B2 | Methods for treating a tumor using an antibody that specifically binds HMW-MAA | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296811-B2 | Methods for treating a tumor using an antibody that specifically binds HMW-MAA | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-21 | — | — | US | disclosed |
| US-8771687-B2 | Methods for treating a tumor using an antibody that specifically binds GRP94 | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-07-08 | — | — | US | disclosed |
| US-6344476-B1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION | 2002-02-05 | — | — | US | disclosed |
| US-20010006975-A1 | Raf kinase inhibitors | BAYER CORPORATION AND ONYX PHARMACEUTICALS WEST HAVEN, CT AND RICHMOND, CA, RESPECTIVELY | 2001-07-05 | — | — | US | disclosed |
| US-6187799-B1 | TREATING CANCEROUS CELL GROWTH MEDIATED BY RAF KINASE BY ADMINISTERING SPECIFIED COMPOUNDS, SUCH AS 2-(METHYOXYCARBONYL),3-((4-METHYLPHENYL)UREA),5-ALKYL-THIOPHENE | ONYX PHARMACEUTICALS | 2001-02-13 | — | — | US | disclosed |
| EP-1019040-A4 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER AG (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1019040-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | Bayer Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998052558-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | MAPK1, MAP3K1, MAP3K7 | MAPK14 40/4885RAF1 237/4885ALDH1A1 1139/4885 |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | MAPK1, MAP3K1, MAP3K7 | MAPK14 40/4885RAF1 237/4885ALDH1A1 1139/4885 |
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | LY96, HSPA2, BRAF | MAPK14 1605/4885RAF1 77/4885ALDH1A1 2301/4885 |
| US-20010006975-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK14 239/4885RAF1 2/4885ALDH1A1 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.